[Early detection of prostate cancer: Towards a new paradigm?]

Prog Urol. 2023 Dec;33(15-16):956-965. doi: 10.1016/j.purol.2023.09.016. Epub 2023 Oct 5.
[Article in French]

Abstract

Prostate cancer (PCa) is a public health issue. The diagnostic strategy for PCa is well codified and assessed by digital rectal examination, PSA testing and multiparametric MRI, which may or may not lead to prostate biopsies. The formal benefit of organized PCa screening, studied more than 10 years ago at an international scale and for all incomers, is not demonstrated. However, diagnostic and therapeutic modalities have evolved since the pivotal studies. The contribution of MRI and targeted biopsies, the widespread use of active surveillance for unsignificant PCa, the improvement of surgical techniques and radiotherapy… have allowed a better selection of patients and strengthened the interest for an individualized approach, reducing the risk of overtreatment. Aiming to enhance coverage and access to screening for the population, the European Commission recently promoted the evaluation of an organized PCa screening strategy, including MRI. The lack of screening programs has become detrimental to the population and must shift towards an early detection policy adapted to the risk of each individual.

Keywords: Cancer de la prostate; Dépistage; Détection précoce; Early detection; Organized screening; Prevention; Prostate cancer; Prévention.

Publication types

  • English Abstract

MeSH terms

  • Biopsy
  • Early Detection of Cancer
  • Humans
  • Magnetic Resonance Imaging / methods
  • Male
  • Prostate / pathology
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / pathology

Substances

  • Prostate-Specific Antigen